Veozah

Quote



anonymous said:
How do we sell against it
Click to expand...
The challenges we are facing are going to be significant! The access coverage provided by payers is extremely limited, as our product is categorized as a lifestyle drug, competing against several more affordable alternatives. To secure even a double step coverage, we will likely need to offer substantial discounts that could prove unsustainable. Moreover, the sales forecasts that Bayer is expected to release seem overly ambitious, creating a high bar for performance. Thus, even if we achieve moderate success in the market, it may still fall short when compared to the lofty quotas set by the company.

These hurdles are compounded by weak leadership within our organization. Their lack of responsiveness to the insights and recommendations provided by our consultants—who have valuable perspectives on the product's genuine market potential—could very well be why the Marketing Lead for this product chose to resign. This combination of unrealistic expectations, inadequate support, and poor communication may lead us into a difficult situation moving forward.
 


The Patient Access lead also resigned. Another critical role for the launch. Bayer leadership- exemplary job retaining talent. You’ll get the launches you deserve.
 



























Write your reply...
Top Bottom
Back
Quote